This came despite advice from the U.S. Centers for Disease Control and Prevention (CDC) that everyone should stay up to date with COVID-19 vaccines for the person's age group to help protect against ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...

(Schnirring, 11/12) Novavax yesterday announced that the US Food and Drug Administration (FDA) has released a clinical hold on its new drug application for its COVID-flu combination and standalone flu ...

In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Major Wall Street indices closed lower on Tuesday as investors booked some profits from a post-election rally and turned ...

The indexes had rallied to record highs since the Nov. 5 U.S. election as investors ... Biotech firm Novavax dropped 6% after ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

Wall Street's main indexes were little changed on Tuesday following post-election gains over the past few days.

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

"The purchases into all markets, but specifically U.S. equity markets ... Among other movers, Biotech firm Novavax dropped 6% ...